Abstracts tagged "population studies"

Abstract Number: 1046 • ACR Convergence 2021
Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea
SE RIM CHOI¹, Anna Shin², Joo Young Shin³, Hokyung Choung³, You-Jung Ha², Yun Jong Lee⁴, Eun bong Lee¹, Jin Kyun Park¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Department of Ophthalmology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
Background/Purpose: To examine the risk of ocular comorbidities in a nation-wide cohort of patients with Behçet’s disease (BD) compared to general population in Korea.Methods: We…
Abstract Number: 1057 • ACR Convergence 2021
Impact of Osteoarthritis in Younger Adults
Elizabeth Badley¹, Jessica Wilfong² and Anthony Perruccio¹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Shcroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: OA is a disease frequently perceived as a disease of the elderly and an inevitable result of aging. Consequently, epidemiological and clinical studies of…
Abstract Number: 1121 • ACR Convergence 2021
Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper¹, Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski¹, Eric Wright¹, Craig Beck², Rebecca Robinson³, Edward Casey⁴, Jerry A. Hall³ and Patricia Schepman⁴, ¹Geisinger, Danville, PA, ²Pfizer, Inc., London, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer, Inc., New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease with complex pathogenesis, and it is important to understand a patient's level of severity in order to plan and…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1286 • ACR Convergence 2021
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Pamela Munguía-Realpozo² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Marked regional variation in systemic lupus erythematosus (SLE) mortality may be due to different spectra of local environmental factors. There have been no large…
Abstract Number: 1579 • ACR Convergence 2021
Phenome-Wide Association of Gout Risk Loci
Oleg Stens¹, Vivian Trang², Steven Cao², Robert Terkeltaub¹ and Rany Salem², ¹University of California San Diego School of Medicine, La Jolla, CA, ²University of California San Diego School of Public Health, La Jolla, CA
Background/Purpose: Gout is a complex disease involving changes in urate biology and inflammatory responses, and is associated with comorbidities including metabolic syndrome and cardiorenal disease.…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0541 • ACR Convergence 2020
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
Victoria Furer¹, Clara Weil², Melanie Orin², Gabriel Chodick², Varda Shalev², Yonit Fisher Shoval³, Raanan Cohen³ and Ori Elkayam⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, ³Abbvie, Hod Hasharon, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…
Abstract Number: 0561 • ACR Convergence 2020
Risk Factors for Falls Among Individuals with Knee OA: A Longitudinal Community-based Study
Jessica Wilfong¹, Anthony Perruccio² and Elizabeth Badley², ¹Krembil Research Institute, University Helath Network, Toronto, ON, Canada, ²Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (OA) is a known risk factor for falling, but little is known about what factors contribute to the risk of falling among…
Abstract Number: 0014 • ACR Convergence 2020
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
Fernando López-Gutierrez¹, Antía García-Fernández¹, Jesús Loarce-Martos¹, Laura Calvo-Sanz¹, Ivan Del Bosque-Granero², Veronica Garcia², Boris Blanco-Cáceres¹, Cristina Pijoan-Moratalla¹, Lourdes Villalobos-Sánchez³, Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
Abstract Number: 0562 • ACR Convergence 2020
The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement
Anthony Perruccio¹, Shatabdy Zahid², Calvin Yip³, J Denise Power², Mayilee Canizares², George Heckman⁴ and Elizabeth Badley¹, ¹Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Shirley Huang¹, Xintong Li², Joehl Nguyen², Jacob Robinson², Susan Hogan³, Vimal Derebail³ and Carolyn Thorpe², ¹University of North Carolina at Chapel Hill, Chapel Hill, ²University of North Carolina Eshelman School of Pharmacy, Chapel Hill, ³University of North Carolina Kidney Center, Chapel Hill
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Sandy Lee¹, Patil Injean¹, Paulina Tran², Deepa Panikkath¹ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…
Abstract Number: 0638 • ACR Convergence 2020
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Marta De la Rubia Navarro¹, Roxana Gonzalez Mazario¹, Elena Grau Garcia³, Cristina Alcañiz Escandell³, Inmaculada Chalmeta Verdejo¹, Jorge Juan Fragio Gil¹, Luis Gonzalez Puig⁴, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁵, Elvira Vicens Bernabeu² and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department, HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁵La Fe University Hospital, Valencia
Background/Purpose: In mid-March 2020, state of alarm was declared in Spain due to the novel coronavirus disease 2019 (COVID-19) pandemic. Patients with rheumatic diseases (RD)…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].